FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

Related Articles

Food Ingredients News

NP Nutra Launches Organic Pea Protein Ingredient

04 Mar 2015 --- Nature’s Power Nutraceuticals Corp. (NP Nutra) a leading supplier of premium botanical ingredients has responded to the growing market demand for superior plant-based protein with Organic Pea Protein 80%.

Health & Nutrition News

BEUC Highlights Marketing of Obesogenic Foods to Children in EU

04 Mar 2015 --- European consumer rights campaigner BEUC has highlighted the World Health Organisation’s (WHO) efforts to discourage the marketing of unhealthy foods to children and questioned whether the EU is doing enough to protect children from obesogenic foods.

Food Research

Pharma Explores Innovative Ways to Treat Obesity in Women, says GBI Research

04 Mar 2015 --- With obesity forecast to affect 50% of adult women by 2050, pharmaceutical companies are currently exploring a number of different approaches to treating the condition, which is known to increase the risk of many serious diseases, says business intelligence provider GBI Research.

Health & Nutrition News

Omniactives Introduces High Potency Ginger to Chinese Market

04 Mar 2015 --- OmniActive Health Technologies will introduce Gingever High Potency Ginger for the first time to FI China attendees at this year’s show, (April 1-3) in Shanghai (China). Non-GMO and allergen-free Gingever is a high-potency super-critical fluid extract with 30% bioactives (min 20% gingerols) made from an FDA-acknowledged GRAS (Generally Regarded As Safe) source.

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html